Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 158Lymphoma 156Precursor Cell Lymphoblastic Leukemia-Lymphoma 130Lymphoma, Non-Hodgkin 120Leukemia 119Leukemia, Lymphocytic, Chronic, B-Cell 116Multiple Myeloma 115Lymphoma, Large B-Cell, Diffuse 100Leukemia, Myeloid, Acute 97Hodgkin Disease 82Myelodysplastic Syndromes 78Lymphoma, Follicular 74Lymphoma, Mantle-Cell 72Burkitt Lymphoma 66Lymphoma, B-Cell, Marginal Zone 52Melanoma 49Leukemia, Myelogenous, Chronic, BCR-ABL Positive 48Neoplasms 45Recurrence 38Hematologic Neoplasms 34Lymphoma, Large-Cell, Immunoblastic 33Myeloproliferative Disorders 31Congenital Abnormalities 31Waldenstrom Macroglobulinemia 30Neoplasms, Plasma Cell 30Leukemia, Myelomonocytic, Chronic 30Lymphoma, B-Cell 29Primary Myelofibrosis 27Lymphoma, Large-Cell, Anaplastic 27Leukemia, Myeloid, Accelerated Phase 26

Interventions

Cyclophosphamide 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Advanced Triple Negative Breast Cancer × Cyclophosphamide × Clear all
NCT04927884 2024-06-12

A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies

ImmunityBio, Inc.

Phase 1/2 Terminated
3 enrolled 9 charts
Breast

Advanced Triple Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡